Cancer Letters

Papers
(The H4-Index of Cancer Letters is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board335
Ethnic Diversity and Metabolic Variations in Ovarian Cancer Cells: Implications for Personalized Medicine Strategies292
Versatility of Exosomes for Cancer Therapy282
Editorial Board176
An emerging aspect of cancer neuroscience: A literature review on chemotherapy-induced peripheral neuropathy165
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model157
Nervous system in colorectal cancer148
Bypassing the Tollway; a novel path to TLR4 independent stemness regulation140
Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects136
Editorial Board135
Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching 132
Evaluation and preservation of fertility in patients with hematologic malignancies118
Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer118
CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia110
Corrigendum to “Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations” [619 1 (2025) 217668 1–13]106
Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation103
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance99
The landscape of malignant transition: Unraveling cancer cell-of-origin and heterogeneous tissue microenvironment99
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?98
The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics97
Understanding the significance of biological clock and its impact on cancer incidence96
LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation96
Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer95
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective93
Sialic Acids: Sweet modulators fueling cancer cells and domesticating the tumor microenvironment93
ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma92
FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity89
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma89
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds87
Hormonal and neuronal interactions shaping the brain metastatic microenvironment86
MDSCs in bone metastasis: Mechanisms and therapeutic potential85
TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancer84
Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells81
Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model80
Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells79
Regulation of gut microbiota on immune cell ferroptosis: A novel insight for immunotherapy against tumor77
METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK/T cell lymphoma growth76
Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis75
Intracellular AGR2 transduces PGE2 stimuli to promote epithelial–mesenchymal transition and metastasis of colorectal cancer74
Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 273
KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA72
Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth72
The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives70
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes69
CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy69
Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives69
PROTACs: Novel tools for improving immunotherapy in cancer68
Ubiquitin-specific peptidase 22 in cancer68
Hypoxia effects on glioblastoma progression through YAP/TAZ pathway regulation67
Tumor-targeted exosomes for delivery of anticancer drugs67
A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma66
Osteopontin promotes tumor microenvironment remodeling and therapy resistance65
Fatty acids in cancer chemoresistance63
Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove data63
Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer62
Tuning cellular metabolism for cancer virotherapy61
The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling61
CD155 in tumor progression and targeted therapy61
PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma60
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy60
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance60
M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP160
Clinical development of immuno-oncology therapeutics60
0.10859107971191